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Abstract
Background: Lipoprotein-associated phospholipase A2 (LpPLA2) levels are associated with stroke, though whether this
extends to all populations and stroke subtypes is unknown.
Methods: Serum samples from stroke-free community participants in the Northern Manhattan Study were assayed for
LpPLA2 mass and activity. Participants were followed annually for stroke. Cox-proportional-hazard models were fitted to
estimate hazard-ratios and 95% confidence intervals (HR, 95% CI) for the association of LpPLA2 levels with ischemic stroke
(IS), after adjusting for demographic and medical risk factors.
Results: Serum samples were available in 1946 participants, of whom 151 (7.8%) experienced a first IS during median follow-
up 11 years. Mean age was 69 (SD 10), 35.6% were men, 20% non-Hispanic Whites, 22% non-Hispanic Blacks, and 55%
Hispanics. LpPLA2 mass and activity levels were not associated with overall IS risk. LpPLA2 mass but not activity levels
were associated with strokes due to large artery atherosclerosis (LAA; adjusted HR per SD 1.55, 95% CI 1.17–2.04). There was
a dose-response relationship with LAA (compared to first quartile, 2nd quartile HR = 1.43, 95% CI 0.23–8.64; 3rd quartile
HR = 4.47, 95% CI 0.93–21.54; 4th quartile HR = 5.07, 95% CI 1.07–24.06). The associations between LpPLA2-mass and LAA-
stroke risk differed by race-ethnicity (p = 0.01); LpPLA2-mass was associated with increased risk of LAA among non-Hispanic
Whites (adjusted HR per SD 1.44, 95% CI 0.98–2.11), but not other race-ethnic groups.
Conclusion: LpPLA2-mass levels were associated with risk of atherosclerotic stroke among non-Hispanic White participants,
but not in other race-ethnic groups in the cohort. Further study is needed to confirm these race-ethnic differences and the
reasons for them.
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Introduction
Stroke is the fourth leading cause of death in the United States
and the leading cause of functional impairment [1]. Because stroke
is largely preventable, tailoring treatment based on estimated risk
may target therapies to high-risk patients and reduce burden of
disease. For this purpose, the measurement of soluble biomarkers,
which indicate underlying subclinical pathological processes, could
be an important adjunct to traditional risk assessment. A highly
promising candidate biomarker for risk stratification is lipoprotein-
associated phospholipase A2 (LpPLA2).
Experimental data indicates that LpPLA2 has important pro-
inflammatory effects specifically affecting vessel walls [2]. Clinical
data using intravascular ultrasound suggests that elevated levels
and increased activity of LpPLA2 are related to the progression of
atherosclerotic disease [3]. Levels of LpPLA2 mass and activity
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were strongly associated with increased risk of cardiovascular
events (either MI or composite endpoints) in several large cohort
studies and meta-analyses [4]. Darapladib, a potential therapeutic
agent specifically targeting LpPLA2 activity, is currently under
investigation as a treatment administered after acute coronary
syndromes and for stable coronary disease [5,6].
Compared to the plethora of studies concerning LpPLA2 and
cardiovascular events, only a few population-based studies have
specifically addressed the association of LpPLA2 mass and activity
and ischemic stroke as a primary outcome. The available data
suggests that among those without a history of stroke, the risk of
stroke is approximately doubled among those with the highest
levels of LpPLA2, compared to those with the lowest levels [7].
The risk of recurrent stroke is similarly elevated among those with
a first stroke [8,9].
We hypothesized that LpPLA2 levels would be associated with
stroke risk in the stroke-free population of Northern Manhattan,
and we further sought to determine whether associations differed
by race-ethnicity and stroke subtype.
Methods
Ethic statement
This study received approval from the institutional review
boards at Columbia University Medical Center and the University
of Miami, and all participants directly or through a surrogate
when appropriate, gave their written informed consent for the
study.
Participants
The Northern Manhattan Stroke (NOMAS) study is a
prospective, population-based cohort study consisting of 3298
stroke-free multiethnic participants enrolled between 1993–2001.
The primary goals of the study were to describe the prevalence of
vascular risk factors and incidence of vascular outcomes in a
community-based sample of a racially and ethnically diverse
population, as previously described [10]. Briefly, participants were
$40 years at enrollment and resided in northern Manhattan, New
York. The race/ethnic distribution of this cohort consists of 63%
Hispanics, 20% non-Hispanic Black, and 15% non-Hispanic
White residents.
Participants underwent a thorough baseline examination
including comprehensive medical history, physical examination,
review of medical records, and fasting blood samples, as previously
described [10]. Trained bilingual research assistants performed
interviews; study physicians conducted physical and neurological
examinations. To assess medical history, standardized questions
were adapted from the Behavioral Risk Factor Surveillance
System by the Centers for Disease Control and Prevention [11].
Race-ethnicity was self-identified by participants using standard
census questions.
Biomarker measurement
Blood samples collected at enrollment were centrifuged and
frozen at280uC in 1 ml aliquots until the time of analysis. For this
analysis, samples were available in 1946 participants. The
available samples were shipped on dry ice. On arrival they were
thawed to 4uC prior to measurements and analyzed within one
hour thereafter, thus reducing pre-analytic problems. Serum
samples were assayed for levels of LpPLA2 mass, using a manual
enzyme-linked immunoassay (PLAC), and LpPLA2 activity, using
a colorimetric activity method (CAM), at a central laboratory at
diaDexus, Inc., San Francisco, CA, USA. Quality control was
maintained using standardized procedures including running
samples in duplicate. All testing was performed in a batch analysis
blinded to all clinical data including outcome.
Prospective Outcome Assessment
Annual telephone follow-up assessed vital status as well as
interval hospitalization or illness and specifically symptoms
indicative of ischemic stroke; the average annual contact rate
was 99% [12]. A positive screen for suspected ischemic stroke was
followed up by in-person assessment to determine whether an
outcome had occurred. We prospectively screened all admissions
and discharges to detect hospitalizations and outcomes that may
not have been captured by telephone interview. Stroke was
defined as the first symptomatic occurrence of fatal and non-fatal
ischemic stroke according to the World Health Organization
criteria [13]. Ischemic stroke subtype was classified by a consensus
of two study neurologists, with a third neurologist adjudicating if
needed [14], based on the TOAST (Trial of Org 10172 in Acute
Stroke Treatment) criteria [15].
Statistical Analyses
Descriptive statistics were calculated, including means for
continuous variables and proportions for dichotomous variables.
The primary outcome for this analysis was ischemic stroke and the
secondary outcome was large artery atherosclerotic stroke (LAA).
The main predictors were LpPLA2 mass and activity considered
as continuous predictors and also by quartiles in order to facilitate
clinical interpretation. We fitted Cox proportional hazard models
to calculate hazard ratios and 95% confidence intervals (HR, 95%
CI), unadjusted and adjusted for demographic and vascular risk
factors, including lipid levels. Adjusted covariates were predictors
of ischemic stroke in prior analyses in NOMAS and traditionally
accepted risk factors for stroke. We tested for interactions between
LpPLA2 and sociodemographic and vascular risk factors. The
interaction models were also fully adjusted using the same
variables as in the Cox proportional hazard models. The final
models were tested to ensure no violation of the proportionality
assumption for the Cox model. We ran sensitivity analyses using
the inverse probability weighted (IPW) method to correct for
potential selection bias that may have been introduced when the
LpPLA2 cohort were selected from the full NOMAS cohort. All
testing was two-tailed and p,0.05 was considered to indicate
statistical significance. All calculations were performed using SAS
v9.1.3 (SAS Institute, Cary, NC).
Results
Study population characteristics
Among 3298 in the stroke free cohort, LpPLA2 levels were
available for 1946 participants. The current study population
consisted of 35.6% men; mean age was 69 (SD6 10) years, 20%
were non-Hispanic Whites, 22% non-Hispanic Blacks, and 55%
Hispanics. Mean LpPLA2 mass levels were 308.7 ng/mL (SD
88.2), and mean LpPLA2 activity levels 116.9 nmol/min/mL (SD
29.6). Characteristics among these participants were similar to
those not in this analysis; this study cohort was slightly younger
(mean age 69 versus 70), and participants were more likely to be
female (64% versus 61%), Hispanic (55% versus 48%), or suffer
from diabetes mellitus (24% versus 18%), and they were more
likely to be physically inactive (55% versus 62%), and less likely to
complete high school (44% versus 49%). We present all baseline
characteristics according to race ethnicity (table 1).
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Association of LpPLA2 levels with incident ischemic
stroke
Among the 1946 participants, 151 (7.8%) developed an
ischemic stroke during a median follow-up of 11 years. Stroke
etiologies according to the TOAST criteria were distributed as
follows: 26 (17%) LAA, 35 (23%) small vessel, 54 (36%)
cardioembolic, and 36 (24%) unknown etiology.
In the adjusted analysis, LpPLA2 mass (adjusted HR per SD
1.02, 95% CI 0.86–1.19) and activity (0.88, 95% CI 0.71–1.08)
were not associated with ischemic stroke (see table 2). There was
also no association when analyzing LpPLA2 mass and activity by
quartiles.
Association of LpPLA2 and large artery atherosclerotic
strokes (LAA)
LpPLA2 mass but not activity levels were associated with LAA
(adjusted HR per SD 1.55, 95% CI 1.17–2.04). When analyzed by
quartiles, there was a dose-response relationship: compared to the
lowest quartile of LpPLA2 mass, there was an increased risk for
those in the second (adjusted HR=1.43, 95% CI 0.23–8.64), third
(adjusted HR=4.47, 95% CI 0.93–21.54), and fourth quartiles
(adjusted HR=5.07, 95% CI 1.07–24.06; table 3). LpPLA2 mass
was not associated with cardioembolic stroke (adjusted HR per SD
0.91, 95% CI 0.69–1.20), or lacunar stroke (adjusted HR per SD
0.69, 95% CI 0.46–1.05).
Sensitivity analyses using the inverse probability weighted
method to correct for potential selection bias that may have been
introduced when the LpPLA2 cohort was selected from the full
NOMAS cohort demonstrated qualitatively similar results (data
not shown).
Modification of the association of Lp-PLA2 by race-
ethnicity
There was a non-significant trend toward effect modification of
the association between LpPLA2 mass and all ischemic strokes by
race-ethnicity (likelihood ratio test with 2 degrees of freedom,
p= 0.14). The effect of LpPLA2 mass on the risk of IS was greater
in non-Hispanic Whites (adjusted HR per SD 1.44, 95% CI 0.98–
2.11), compared to Blacks (adjusted HR per SD 0.88, 95% CI
Table 1. Baseline characteristics according to race ethnicity.
Sociodemographic factors Whole cohort Hispanic Non-Hispanic White Non-Hispanic Black P-value1
N 1946 1059 381 425
Age, mean 6 SD (years) 69610 6669 73610 72611 ,0.0001
Female sex, n (%) 1253 (64%) 682 (64%) 237 (61%) 300 (70%) 0.02
Education (High School graduate), n (%) 856 (44%) 222 (21%) 328 (85%) 266 (62%) ,0.0001
Vascular risk factors
Hypertension*, n (%) 1447 (74%) 813 (76%) 253 (65%) 350 (82%) ,0.0001
Systolic blood pressure, mean 6 SD (mmHG) 144620 143621 140620 148621 ,0.0001
Coronary heart disease, n (%) 429 (22%) 218 (20%) 101 (26%) 97 (23%) 0.06
Diabetes mellitus, n (%) 467 (24%) 282 (26%) 56 (15%) 121 (28%) ,0.0001
Waist circumference, mean 6 SD 36.864.9 3765 3665 3765 0.006
Any physical activity, n (%) 1067 (55%) 521 (49%) 250 (64%) 261 (61%) ,0.0001
Past smoker, n (%) 674 (35%) 344 (32%) 158 (41%) 150 (35%) ,0.0001
Current smoker, n (%) 347 (18%) 179 (17%) 56 (14%) 103 (24%)
Moderate alcohol consumption**, n (%) 647 (33%) 322 (30%) 165 (43%) 139 (32%) ,0.0001
Laboratory measurements
LpPLA2, mean 6 SD (mass, ng/ml) 308.7688.2 300.2684.9 349.6682.4 294.9690.8 ,0.0001
LpPLA2, mean 6 SD (activity, nmol/min/mL) 116.9+29.6 114627.7 131.4631.0 109.1628.1 ,0.0001
HDL, mean 6 SD (mg/dL) 46.5614.2 43.5612.9 48.6614.3 51.1615.2 ,0.0001
LDL, mean 6 SD (mg/dL) 129.2635.5 129. 5634.8 132.7634.2 125.5637.6 0.02
SD: standard deviation; IQR: interquartile range.
*Hypertension defined as: history, taking medications, or systolic blood pressure $140 mmHg, or diastolic blood pressure $90 mmHg;
**Moderate alcohol intake: 1 alcoholic drink per week to 2 drinks per day.
1Kruskal Wallis test for continuous variables and Chi-Squared test for categorical variables.
doi:10.1371/journal.pone.0083393.t001
Table 2. Association of LpPLA2 mass and activity with
incident ischemic stroke.
Biomarker levels Hazard Ratio 95%CI
LpPLA2-mass (per SD):
unadjusted 1.03 0.89–1.21
adjusted for demographics* 0.99 0.84–1.16
fully adjusted** 1.02 0.86–1.19
LpPLA2-activity (per SD):
unadjusted 0.92 0.78–1.01
adjusted for demographics* 0.83 0.69–0.99
fully adjusted** 0.88 0.71–1.08
*age, gender, race-ethnicity, education.
**adjusted for age, sex, race-ethnicity, education, waist circumference, physical
activity, moderate alcohol consumption, smoking status, diabetes mellitus,
systolic blood pressure, coronary artery disease, Low density lipoprotein, High
density lipoprotein.
doi:10.1371/journal.pone.0083393.t002
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,0.0001
0.66–1.17) and Hispanics (adjusted HR per SD 1.01, 95% CI
0.79–1.28) (see table 4).
Each stroke etiology had different distributions of race-ethnicity.
The proportion of strokes due to LAA was 24% among non-
Hispanic Whites, 10% among non-Hispanic Blacks and 17%
among Hispanics, whereas small vessel stroke was the etiologic
subtype in 31% of non-Hispanic Blacks and 22% of Hispanics, but
only 17% of non-Hispanic Whites. The proportion of cardioem-
bolic stroke was 31% among non-Hispanic Whites, 46% among
non-Hispanic Blacks and 33% among Hispanics.
The association of LpPLA2 mass with LAA stroke differed
significantly by race-ethnicity (likelihood ratio test with 2 degrees
of freedom, p= 0.01). LpPLA2 was associated with increased risk
of LAA among non-Hispanic Whites (adjusted HR per SD 3.05,
95% CI 1.92–4.85), but not Blacks (adjusted HR per SD 1.19,
95% CI 0.70–2.05) or Hispanics (adjusted HR per SD 1.26, 95%
CI 0.70–2.05) (see table 5). These interactions were not seen when
analyzing LpPLA2 activity.
Discussion
In this urban multiethnic population-based sample we found
that LpPLA2 mass levels previously associated with vascular
disease risk are associated with risk of large artery atheroscle-
rotic stroke, and the association was most prominent among
non-Hispanic White participants, but not in other race-ethnic
groups. We did not find an association of LpPLA2 with overall
ischemic stroke risk.
There is limited data on the association of LpPLA2 levels and
specific stroke etiologic subtypes. LpPLA2, a marker of inflam-
mation and atherosclerosis, has been associated with coronary
artery disease and myocardial disease. The causes of ischemic
stroke are more heterogeneous than those of atherosclerotic heart
disease, however, and considering all ischemic stroke as one
disease for the purposes of these analyses may underestimate
effects of particular risk factors. For example, several early
epidemiologic studies indicated a lack of association between
stroke risk and elevated lipid levels, but generally did not
distinguish between stroke subtypes [16]. In recent studies,
however, it has been demonstrated that lipids are risk factors
specifically for large artery atherosclerotic strokes [17]. These
findings supported our hypothesis that LpPLA2 may be associated
with large artery atherosclerotic stroke risk, but not overall
ischemic stroke risk. We did not find associations of LpPLA2 mass
levels with lacunar strokes, arising from lipohyalinosis of small
perforating arteries, which are generally considered to be related
to hypertension and diabetes, or with cardioembolic stroke, related
to the formation of thrombin-rich clots that form in the heart,
often in the presence of atrial fibrillation. Further indirect evidence
Table 3. Association of LpPLA2 with large-artery atherosclerotic (LAA) stroke.
Biomarker levels
Unadjusted
HR (95% CI)
Model 1*,
HR (95% CI)
Model 2**,
HR (95% CI)
LpPLA2-mass (per SD) 1.57 (1.26–1.96) 1.49 (1.18–1.88) 1.55 (1.17–2.04)
LpPLA2-activity (per SD) 1.34 (0.92–1.94) 1.15 (0.76–1.73) 1.17 (0.71–1.92)
LpPLA2-mass (the number of LAA, levels)
Q1 (n = 2, 28.1–245.6) Ref. Ref. Ref.
Q2 (n = 3, 245.7–307.2) 1.53 (0.26–9.15) 1.42 (0.24–8.52) 1.43 (0.23–8.46)
Q3 (n = 9, 307.2–365.5) 4.63 (1.00–21.44) 4.09 (0.88–19.12) 4.47 (0.93–21.54)
Q4 (n = 12, 365.5–972.6) 6.19 (1.39–27.64) 4.88 (1.06–22.45) 5.07 (1.07–24.06)
LpPLA2-activity (the number of LAA, levels)
Q1 (n = 5, (12.1–96.5) Ref. Ref. Ref.
Q2 (n = 4, 96.6–115.5) 0.69 (0.19–2.61) 0.67 (0.18–2.56) 0.67 (0.18–2.56)
Q3 (n = 9, 115.6–135.9) 1.43 (0.47–4.37) 1.43 (0.43–4.72) 1.43 (0.43–4.72)
Q4 (n = 8, 136.0–220.9) 0.98 (0.29–3.29) 0.87 (0.33–3.48) 0.87 (0.22–3.48)
*Model 1; adjusted for demographics (i.e. age, gender, race-ethnicity, education).
**Model 2; adjusted for demographics & medical risk factors (i.e. age, sex, race-ethnicity, education, waist circumference, physical activity, moderate alcohol
consumption, smoker, diabetes mellitus, systolic blood pressure, coronary artery disease, LDL, HDL).
doi:10.1371/journal.pone.0083393.t003
Table 4. Stratification by race ethnicity for all ischemic stoke.
Race-ethnicity group HR* of LpPLA2-mass 95% CI of HR
White 1.44 0.98 2.11
Black 0.88 0.66 1.17
Hispanic 1.01 0.80 1.28
*adjusted for age, sex, race-ethnicity, education, waist circumference, physical
activity, moderate alcohol consumption, smoking status, diabetes mellitus,
systolic blood pressure, coronary artery disease, Low density lipoprotein, High
density lipoprotein.
doi:10.1371/journal.pone.0083393.t004
Table 5. Stratification by race ethnicity for large-artery
atherosclerotic (LAA) stroke.
Race-ethnicity group HR* of LpPLA2-mass 95% CI of HR
White 3.05 1.92 4.85
Black 1.20 0.7 2.05
Hispanic 1.26 0.77 2.06
*adjusted for age, sex, race-ethnicity, education, waist circumference, physical
activity, moderate alcohol consumption, smoking status, diabetes mellitus,
systolic blood pressure, coronary artery disease, Low density lipoprotein, High
density lipoprotein.
doi:10.1371/journal.pone.0083393.t005
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in support of this hypothesis may be drawn from a recently
published study of a population of patients with transient ischemic
attacks in which LpPLA2 activity was increased specifically when
LAA was the most likely mechanism for the TIA [18]. Moreover,
others have shown that LpPLA2 expression was significantly
higher in the carotid plaque of symptomatic patients, in particular
in those with TIA [19].
We have previously reported that LpPLA2 mass as well as
activity levels in the top quartile predict recurrent stroke after first
ischemic stroke [8]. These findings seem not to be consistent with
the lack of association of LpPLA2 with ischemic stroke risk in the
present study. However, the effect of LpPLA2 on the risk of
recurrent stroke appeared to be greater for those with previous
atherosclerotic strokes [8]. Moreover, the population of incident
stroke patients differs from the stroke-free population, such that
subjects with a first stroke are likely in a very high vascular risk
category compared to the stroke free population. Therefore the
predictive value of LpPLA2 may differ.
We also found that the association of LpPLA2 with risk of
atherosclerotic stroke differed by race-ethnic group; the effect of
LpPLA2 on LAA risk was greater among non-Hispanic Whites
compared to non-Hispanic Blacks or Hispanics. It thus may be
that risk factors for large vessel atherosclerosis are not exactly the
same in all ethnicities, or that the effect of other risk factors, like
diabetes or hypertension, are more important than LpPLA2 in
other race-ethnic groups. Studies on the value of LpPLA2 mass
and/or activity levels in the prediction of stroke risk have been
carried out predominantly in Caucasian populations, and differ-
ences in LpPLA2 across race-ethnicities have been reported [20].
Of the four largest population studies, including the Rotterdam
study cohort [21], the Malmo¨ Diet and Cancer Study (MDCS)
[22], the Women’s Health Initiative Observational Study (WHI-
OS) [23] and the Atherosclerosis Risk in Communities (ARIC)
[24] study, only ARIC and WHI-OS included a relatively large
proportion of Blacks. Hispanics have not been studied with regard
to LpPLA2 and stroke risk. Although similar well-known vascular
risk factors and molecular pathways are involved in the global
process of atherogenesis, local expression and severity of athero-
sclerosis differs among vulnerable individuals. A paradigm of this
disparity is the difference in race-ethnic distribution of atheroscle-
rosis. Carotid bifurcation atherosclerosis, for example, appears to
be most prevalent among Caucasians compared to African
Americans, Hispanics or Asians [25–29]. Our study is the first
assessing LpPLA2 as a potential risk factor for incident ischemic
stroke events in a multiethnic cohort including a large proportion
of Hispanics. This large proportion of Hispanics may explain why
LpPLA2 levels were not associated with all ischemic stroke in our
cohort and why in contrast in other primarily European
Caucasian populations in which LAA may be a relatively more
prominent subtype [30] investigators found an association of
LpPLA2 with all ischemic stroke.
Stroke etiology in the present cohort differed by race-ethnicity.
Whites were more likely to have LAA than Blacks or Hispanics,
but less likely to have small vessel disease than other race-ethnicity.
These distributions were consistent with other studies. In the
South London Ethnicity and Stroke study, the proportion of LAA
was greater among Whites (14.3%) than among Blacks (8%)
whereas small vessel disease was much more common among
Blacks (33%) compared to Whites (14%) [25]. In the Rochester
Epidemiology Project the incidence of stroke due to large-vessel
atherosclerosis with stenosis was significantly greater among
Whites (27 per 100 000) than Blacks (17 per 100 000) [31].
We found associations for LpPLA2 mass levels but not activity
levels. We previously found that mass levels were more strongly
associated than activity levels with outcomes after incident stroke
in our cohort [8,9]. LpPLA2 activity is also more strongly
associated with lipid markers then mass [4] and, as we previously
reported, baseline lipid panel components were not clearly
associated with an increased stroke risk in this cohort [32],
possibly because of temporal trends in use of statins and levels of
lipids. Further possible reasons for differences between mass and
activity levels as prognostic markers include acute changes in
activity levels in the setting of lipoprotein changes.
Our study has limitations. First, the blood samples were stored
at 280 C for several years, which could potentially lead to some
protein degradation. However, LpPLA2 seems to be quite stable
over time when stored at 270 C [33]. Moreover our samples were
stored for a similar length of time as compared to other studies [4].
Second, we did not have blood available for analysis in all
participants in our cohort, but the differences between our entire
cohort and the sample analyzed in this study were minimal. Third,
repeated measurements of LpPLA2 and measurements closer to
the event or their change over time may be a better or of ischemic
stroke than levels measured at a single baseline point. Fourth,
there are shortcomings with all etiological classifications of
ischemic stroke and it is always difficult to determine stroke
subtype with certainty. In the NOMAS cohort we tried to
minimize misclassification by relying only on a consensus among
vascular neurologists, with a third neurologist adjudicating if
needed [14]. If misclassification occurred it would rather be non-
differential misclassification due to missed cases thus underesti-
mating the association of LpPLA2 and LAA strokes. Fifth, self-
report of race-ethnicity depends on cultural and social character-
istics and is not equivalent to a biological marker or genetic
indicator. Finally, as the number of LAA strokes is relatively small,
analyses by race-ethnicity groups should be considered with
caution and differences observed may be due to chance. Although
the magnitude of association may be over- or underestimated, and
thus the precision of the point estimates may be limited, we are
confident that the associations we found are reliable. But these
results need external validation.
The strengths of this study include the population-based
multiethnic cohort, including a large proportion of Hispanics
who are frequently underrepresented in other cohort studies,
minimal loss to follow-up, and the ability to adjust for numerous
potential covariates. Moreover, we were able to assess stroke
etiology and potential interactions, and we ran sensitivity analyses
to exclude biases due to selection of the subsample.
If our results are confirmed, this could have potential clinical
implications. For example it may be that stroke risk reduction
strategies aimed at targeting LpPLA2 inhibition will have
differential benefits across different ethnicities. Concerning poten-
tial primary prevention trials with the LpPLA2 inhibitor
darapladib it will be important to adequately select patients who
are most likely to benefit.
In conclusion, our study aimed at investigating the association of
LpPLA2 with incident ischemic stroke in a multiethnic cohort.
LpPLA2 mass levels were associated with risk of atherosclerotic
stroke among non-Hispanic White participants, but not in other
race-ethnic groups in this cohort. Further study is needed to
confirm these race-ethnic differences and the reasons for them.
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